Eli Lilly’s diabetes drug tirzepatide gets approval in China By Reuters
SHANGHAI (Reuters) - Eli Lilly (NYSE:) said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting...
tirzepatide
SHANGHAI (Reuters) - Eli Lilly (NYSE:) said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting...
